Remibrutinib: all 35 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruitingNCT07855276Phase 1
• Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingNCT07816328Phase 3
• A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingNCT07811869Phase 3
• A 52-week Study of Remibrutinib in IgE-mediated Food AllergyRecruitingNCT07768371Phase 3
• A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingNCT07700056Phase 3
• A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)RecruitingNCT07681271Phase 2
• An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruitingNCT07665437Phase 3
• Remibrutinib Open Label Roll-over Post-trial Access ProtocolRecruitingNCT07456891Phase 3
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruitingNCT07225504Phase 3
• A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MSNot yet recruitingNCT07222956Phase 2
• Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaRecruitingNCT06865651Phase 2
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingNCT06846281Phase 3
• A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.CompletedNCT05795153Phase 3Results posted
• Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to PeanutsCompletedNCT05432388Phase 2Results posted
• A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistaminesCompletedNCT05048342Phase 3Results posted
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistaminesCompletedNCT05032157Phase 3Results posted
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 AntihistaminesCompletedNCT05030311Phase 3Results posted
• An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSUCompletedNCT04109313Phase 2Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma PatientsTerminatedNCT03944707Phase 2Results posted
• This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistaminesCompletedNCT03926611Phase 2Results posted
• Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03827798Phase 2Results posted
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.CompletedNCT07032272Phase 1
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingNCT06868212Phase 3
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06840392Phase 3
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active, not recruitingNCT06799000Phase 3
• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT06744920Phase 3
• Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active, not recruitingNCT06042478Phase 3
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive, not recruitingNCT05976243Phase 3
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy ParticipantsCompletedNCT05753592Phase 1
• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive, not recruitingNCT05677451Phase 3
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With RemibrutinibActive, not recruitingNCT05513001Phase 3
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active, not recruitingNCT05156281Phase 3
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active, not recruitingNCT05147220Phase 3
• Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064CompletedNCT03918980Phase 1

← Remibrutinib overview